Physician profile
Kamel Hatahet
NPI 1235417023
$2,317.23
in general payments reported to CMS, 2019-2025
19 companies · $673 in 2025
The $673 reported for 2025 was more than what a typical Nephrology (Internal Medicine) provider received nationally (typical 2025 total: $311).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $200 · 2021: $84.82 · 2022: $270 · 2023: $641 · 2024: $448 · 2025: $673.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,704 · Education: $58.76.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,703.53 |
| Education | $58.76 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Calliditas Therapeutics US INC. | $330.25 | 2023-2025 | Tarpeyo |
| Bayer Healthcare Pharmaceuticals INC. | $324.79 | 2021-2025 | |
| Travere Therapeutics, INC. | $262.40 | 2022-2025 | |
| Vifor Pharma, INC. | $210.95 | 2019-2023 | Korsuva, Veltassa |
| Novartis Pharmaceuticals Corporation | $196.82 | 2019-2025 | |
| Astrazeneca Pharmaceuticals LP | $192.80 | 2019-2025 | Farxiga |
| Otsuka America Pharmaceutical, INC. | $175.87 | 2019-2025 | Jynarque, Voyxact |
| Glaxosmithkline, LLC. | $132.58 | 2023-2025 | Benlysta, Jesduvroq |
| Novo Nordisk INC | $123.54 | 2023-2025 | Ozempic, Rybelsus |
| Amgen INC. | $99.05 | 2022-2025 | Tavneos, Aranesp |
| Akebia Therapeutics INC | $69.88 | 2019-2022 | |
| Opko Pharmaceuticals, LLC | $45.92 | 2019 | |
| Ardelyx, INC. | $41.87 | 2024-2025 | Ibsrela |
| Otsuka Pharmaceutical Development & Commercialization, INC. | $20.99 | 2023 | Jynarque |
| Genzyme Corporation | $20.14 | 2023 |
Show all 19 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Fresenius USA Marketing, INC. | $18.73 | 2025 | Velphoro |
| Boehringer Ingelheim Pharmaceuticals, INC. | $17.97 | 2023 | Jardiance |
| Ani Pharmaceuticals, INC. | $17.53 | 2023 | Purified Cortrophin Gel |
| Horizon Therapeutics Plc | $15.15 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Kamel Hatahet listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.